Bosutinib: Management of Adverse Events in Chronic Myeloid Leukemia

Bosutinib—a tyrosine kinase inhibitor FDA-approved for newly diagnosed chronic myeloid leukemia (CML) or resistant CML based on data from the phase 3 BFORE trial—is associated with gastrointestinal side effects, liver enzyme abnormalities, myelosuppression, skin disorders, renal dysfunction, and cardiac events. To help physicians navigate these potential side effects and keep patients on treatment, an expert panel has provided recommendations on the best approaches to managing adverse events in patients taking bosutinib, such as taking medication with food.

Cancer Therapy Advisor